Supplementary Table S2: summary of 47 KEGG pathways significantly enriched. 
ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
hsa05140	Leishmaniasis	8/42	77/8164	3.94E-09	5.59E-07	3.69E-07	HLA-DMB/CYBB/ITGB2/HLA-DMA/C3/HLA-DQB1/FOS/HLA-DRA	8
hsa05152	Tuberculosis	10/42	180/8164	1.69E-08	8.50E-07	5.61E-07	HLA-DMB/FCER1G/CTSS/ITGB2/IL10RA/HLA-DMA/C3/HLA-DQB1/HLA-DRA/CD14	10
hsa05323	Rheumatoid arthritis	8/42	93/8164	1.80E-08	8.50E-07	5.61E-07	HLA-DMB/CXCL6/ITGB2/HLA-DMA/CCL5/HLA-DQB1/FOS/HLA-DRA	8
hsa04145	Phagosome	9/42	152/8164	5.60E-08	1.99E-06	1.31E-06	HLA-DMB/CTSS/CYBB/ITGB2/HLA-DMA/C3/HLA-DQB1/HLA-DRA/CD14	9
hsa05310	Asthma	5/42	31/8164	4.34E-07	1.06E-05	6.98E-06	HLA-DMB/FCER1G/HLA-DMA/HLA-DQB1/HLA-DRA	5
hsa05150	Staphylococcus aureus infection	7/42	96/8164	4.81E-07	1.06E-05	6.98E-06	HLA-DMB/ITGB2/HLA-DMA/C3/HLA-DQB1/HLA-DRA/DEFB1	7
hsa05416	Viral myocarditis	6/42	60/8164	5.21E-07	1.06E-05	6.98E-06	HLA-DMB/ITGB2/HLA-DMA/RAC2/HLA-DQB1/HLA-DRA	6
hsa04061	Viral protein interaction with cytokine and cytokine receptor	7/42	100/8164	6.36E-07	1.13E-05	7.45E-06	CX3CR1/CXCL6/IL10RA/CCL5/TNFSF10/CXCL9/CXCL14	7
hsa04514	Cell adhesion molecules	8/42	157/8164	1.06E-06	1.67E-05	1.10E-05	HLA-DMB/ITGB2/PTPRC/HLA-DMA/SDC1/HLA-DQB1/VCAM1/HLA-DRA	8
hsa04060	Cytokine-cytokine receptor interaction	9/42	295/8164	1.45E-05	0.000205736	0.000135734	CX3CR1/CXCL6/IL10RA/CCL5/TNFSF10/CXCL9/IL32/CXCL14/GDF15	9
hsa05330	Allograft rejection	4/42	38/8164	3.94E-05	0.000470472	0.000310393	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA	4
hsa05133	Pertussis	5/42	76/8164	3.98E-05	0.000470472	0.000310393	CXCL6/ITGB2/C3/FOS/CD14	5
hsa04612	Antigen processing and presentation	5/42	78/8164	4.51E-05	0.000470472	0.000310393	HLA-DMB/CTSS/HLA-DMA/HLA-DQB1/HLA-DRA	5
hsa04062	Chemokine signaling pathway	7/42	192/8164	4.79E-05	0.000470472	0.000310393	CX3CR1/CXCL6/CCL5/HCK/RAC2/CXCL9/CXCL14	7
hsa04650	Natural killer cell mediated cytotoxicity	6/42	131/8164	4.97E-05	0.000470472	0.000310393	FCER1G/ITGB2/CD48/TNFSF10/RAC2/TYROBP	6
hsa05332	Graft-versus-host disease	4/42	42/8164	5.88E-05	0.000521731	0.000344211	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA	4
hsa04940	Type I diabetes mellitus	4/42	43/8164	6.46E-05	0.000539391	0.000355862	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA	4
hsa04658	Th1 and Th2 cell differentiation	5/42	92/8164	9.97E-05	0.000786544	0.000518921	HLA-DMB/HLA-DMA/HLA-DQB1/FOS/HLA-DRA	5
hsa04672	Intestinal immune network for IgA production	4/42	49/8164	0.000108416	0.000810267	0.000534572	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA	4
hsa04640	Hematopoietic cell lineage	5/42	99/8164	0.000141218	0.000998211	0.000658568	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA/CD14	5
hsa05320	Autoimmune thyroid disease	4/42	53/8164	0.000147623	0.000998211	0.000658568	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA	4
hsa04659	Th17 cell differentiation	5/42	108/8164	0.000212722	0.001340082	0.000884117	HLA-DMB/HLA-DMA/HLA-DQB1/FOS/HLA-DRA	5
hsa05164	Influenza A	6/42	171/8164	0.000217056	0.001340082	0.000884117	HLA-DMB/HLA-DMA/CCL5/TNFSF10/HLA-DQB1/HLA-DRA	6
hsa05145	Toxoplasmosis	5/42	112/8164	0.000252168	0.001491993	0.000984339	HLA-DMB/IL10RA/HLA-DMA/HLA-DQB1/HLA-DRA	5
hsa05321	Inflammatory bowel disease	4/42	65/8164	0.000326415	0.001854038	0.001223198	HLA-DMB/HLA-DMA/HLA-DQB1/HLA-DRA	4
hsa05322	Systemic lupus erythematosus	5/42	136/8164	0.000617868	0.003374508	0.002226325	HLA-DMB/HLA-DMA/C3/HLA-DQB1/HLA-DRA	5
hsa05417	Lipid and atherosclerosis	6/42	215/8164	0.000738731	0.003885176	0.002563237	CYBB/CCL5/TNFSF10/VCAM1/FOS/CD14	6
hsa05166	Human T-cell leukemia virus 1 infection	6/42	222/8164	0.000873731	0.004431065	0.002923386	HLA-DMB/ITGB2/HLA-DMA/HLA-DQB1/FOS/HLA-DRA	6
hsa05142	Chagas disease	4/42	102/8164	0.001785732	0.00874393	0.00576879	CCL5/C3/FOS/KNG1	4
hsa04620	Toll-like receptor signaling pathway	4/42	104/8164	0.001917918	0.009078143	0.005989287	CCL5/FOS/CXCL9/CD14	4
hsa05144	Malaria	3/42	50/8164	0.002097765	0.009609119	0.006339596	ITGB2/SDC1/VCAM1	3
hsa04668	TNF signaling pathway	4/42	112/8164	0.002514871	0.011159741	0.007362616	CXCL6/CCL5/VCAM1/FOS	4
hsa04670	Leukocyte transendothelial migration	4/42	114/8164	0.002682011	0.011540773	0.007614001	CYBB/ITGB2/RAC2/VCAM1	4
hsa05134	Legionellosis	3/42	57/8164	0.003054507	0.012757059	0.008416444	ITGB2/C3/CD14	3
hsa05169	Epstein-Barr virus infection	5/42	202/8164	0.003567062	0.014472081	0.009547926	HLA-DMB/HLA-DMA/HLA-DQB1/ISG15/HLA-DRA	5
hsa05418	Fluid shear stress and atherosclerosis	4/42	139/8164	0.005456191	0.021521643	0.01419886	SDC1/RAC2/VCAM1/FOS	4
hsa04662	B cell receptor signaling pathway	3/42	82/8164	0.008458844	0.032463672	0.021417841	IFITM1/RAC2/FOS	3
hsa04610	Complement and coagulation cascades	3/42	85/8164	0.009334218	0.034880499	0.023012338	ITGB2/C3/KNG1	3
hsa05210	Colorectal cancer	3/42	86/8164	0.009637372	0.03508992	0.023150503	RAC2/EGF/FOS	3
hsa04657	IL-17 signaling pathway	3/42	94/8164	0.012270231	0.043559321	0.028738173	CXCL6/FOS/S100A8	3
hsa04666	Fc gamma R-mediated phagocytosis	3/42	97/8164	0.013353945	0.046250247	0.030513506	PTPRC/HCK/RAC2	3
hsa05231	Choline metabolism in cancer	3/42	98/8164	0.013726997	0.046410323	0.030619116	RAC2/EGF/FOS	3
hsa05146	Amoebiasis	3/42	102/8164	0.015278639	0.04955874	0.032696277	ITGB2/ARG2/CD14	3
hsa05143	African trypanosomiasis	2/42	37/8164	0.015356229	0.04955874	0.032696277	VCAM1/KNG1	2
hsa04613	Neutrophil extracellular trap formation	4/42	190/8164	0.015966227	0.050382316	0.03323963	CYBB/ITGB2/RAC2/C3	4
hsa04071	Sphingolipid signaling pathway	3/42	119/8164	0.022946512	0.070834886	0.046733172	FCER1G/RAC2/KNG1	3
hsa04810	Regulation of actin cytoskeleton	4/42	218/8164	0.025065458	0.075729683	0.049962504	ITGB2/RAC2/EGF/KNG1	4